United States Minor Cannabinoids Market Insights Forecasts to 2033

• The U.S. Minor Cannabinoids Market Size was valued at USD 11.2 Billion in 2023.
• The Market is growing at a CAGR of 14.87% from 2023 to 2033
• The U.S. Minor Cannabinoids Market Size is expected to reach USD 44.8 Billion by 2033

The United States Minor Cannabinoids Market is anticipated to exceed USD 44.8 Billion by 2033, growing at a CAGR of 14.87% from 2023 to 2033. The growing application of cannabinoid-based products and awareness about their health benefits are driving the growth of the minor cannabinoids market in the US.     

Market Overview

Minor cannabinoids are cannabis-derived compounds that are found in small concentrations in cannabis plants. Cannabigerol (CBG), Cannabinol (CBN), cannabichromene (CBC), and CBDa are the four minor cannabinoids that show incredible health benefits. These chemicals are becoming more and more popular in the wellness and medical industries as research on them deepens and awareness of their unique health advantages grows. Regulations that facilitate the legalization and marketing of items produced from cannabis are important for creating an atmosphere that is favorable to market growth. The market is expanding due in part to an increasing amount of scientific research demonstrating the health advantages of small cannabinoids in the treatment of ailments like anxiety, pain, inflammation, and sleep disturbances. An increasing number of items, such as skincare and supplements, are becoming more widely available, which increases the user base and drives market expansion.

Report Coverage

This research report categorizes the market for the US minor cannabinoids market based on various segments and regions and forecasts revenue growth and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the United States minor cannabinoids market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the US minor cannabinoids market.

Driving Factors

Supplements, topicals, and tinctures are among the wellness items that are increasingly including minor cannabinoids. A variety of cosmetics and personal care products are made with trace amounts of cannabis. For instance, to address customer concerns about skincare, Amyris, Inc., a synthetic biotechnology business, produces clean cannabibigerol, or CBG. The growing emphasis on awareness about the benefits of minor cannabinoids, such as cannabigerol (CBG), tetrahydrocannabivarin (THCV), and cannabinol (CBN), in product formulations by the cannabis industry, is responsible for driving the market expansion. Further, the growing preference of medical professionals for cannabinoid-based formulations to treat a variety of health concerns is contributing to the US minor cannabinoids market.

Restraining Factors

The increased product costs and restrictions on advertising and marketing are restraining the market for minor cannabinoids.

Market Segmentation

The United States Minor Cannabinoids Market share is classified into product type and application.

• The tetrahydrocannabivarin (THCV) segment dominated the market during the forecast period.

The United States minor cannabinoids market is segmented by product type into cannabigerol (CBG), cannabichromene (CBC), cannabinol (CBN), tetrahydrocannabivarin (THCV), cannabigerolic acid (CBGA), and others. Among these, the tetrahydrocannabivarin (THCV) segment dominated the market during the forecast period. The increasing use of THCV for metabolic disorders, neurological disorders, and pain management is driving the market growth in the tetrahydrocannabivarin (THCV) segment.

• The neurological disorders segment dominates the US minor cannabinoids market with a significant revenue share in 2023.       

Based on the application, the U.S. minor cannabinoids market is divided into inflammation, pain management, neurological disorders, cancer, and others. Among these, the neurological disorders segment dominates the US minor cannabinoids market with a significant revenue share in 2023. Patients with multiple sclerosis have demonstrated improvements in their spasticity-related symptoms when using synthetic cannabis drugs like napiximols. The growing incidences of neurological diseases and awareness about the benefits of cannabinoids are driving the market in the neurological disorders segment.  

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the U.S. minor cannabinoids market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Mile High Labs
• GCM Holdings, LLC (Global Cannabinoids)
• Rhizo Sciences
• Laurelcrest
• GenCanna.
• CBD. INC.
• High Purity Natural Products
• Fresh Bros Hemp Company
• BulKanna
• ZERO POINT EXTRACTION, LLC
• Others

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting And Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Recent Developments

• In December 2023, Rare Cannabinoid Company announced the launch of their groundbreaking product, THC + THCV uplift gummies.
• In October 2022, High Tide Inc., a leading retail-focused cannabis company with bricks-and-mortar as well as global e-commerce assets, announced that its Colorado-based subsidiary, NuLeaf Naturals (“NuLeaf”), has had its Full Spectrum Multicannabinoid oil and plant-based softgels with delta-9 tetrahydrocannabinol (“Delta 9”), cannabichromene (“CBC”), cannabidiol (“CBD”), cannabigerol (“CBG”) and cannabinol (“CBN”) listed for sale in Manitoba through the Manitoba Liquor & Lotteries Corporation (“MBLL”).

Market Segment

This study forecasts revenue at U.S., regional, and country levels from 2020 to 2033. Spherical Insights has segmented the United States Minor Cannabinoids Market based on the below-mentioned segments:

US Minor Cannabinoids Market, By Product Type

• Cannabigerol (CBG)
• Cannabichromene (CBC)
• Cannabinol (CBN)
• Tetrahydrocannabivarin (THCV)
• Cannabigerolic Acid (CBGA)
• Others

US Minor Cannabinoids Market, By Application

• Inflammation
• Pain Management
• Neurological Disorders
• Cancer
• Others